Home Administrative Billing & Reimbursement Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Reminder: Updates to the AmeriHealth Pennsylvania medical benefit specialty drug cost-sharing list

November 1, 2018

As a reminder, effective January 1, 2019, AmeriHealth Pennsylvania will update its list of specialty drugs that require member cost-sharing (e.g., copayment, deductible, and coinsurance). Cost-sharing applies to select medical benefit specialty drugs for members who are enrolled in Commercial FLEX products and other select plans. The member's cost-sharing amount is based on the terms of the member's benefit contract. In accordance with your Provider Agreement, it is the provider's responsibility to verify a member’s individual benefits and cost-share requirements.

The list will be expanded to include 161 drugs, including additions of the following:

  • brexanolone*
  • FulphilaTM (pegfilgrastim-jmdb)
  • Ilaris® (canakinumab)
  • Jivi® (recombinant PEGylated-aucl)
  • OnpattroTM (patisiran)
  • ravulizumab*
  • Triptodur® (triptorelin)

In addition, all specialty drugs that are classified by AmeriHealth as Gene Therapy (e.g., LuxturnaTM [voretigene neparvovec-rzyl]) will require member cost-sharing.

The comprehensive list of specialty drugs with cost-sharing is now available on our website.

*Pending approval from the U.S. Food and Drug Administration (FDA).

Cost-sharing applies to all FDA-approved biosimilars to pegfilgrastim.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of AmeriHealth, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey.
© 2023 AmeriHealth Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer